NeOnc Technologies Holdings, Inc. (NTHI)

NGM – Цена в реальном времени. Валюта: USD

3.46

-0.89 (-20.46%)

При закрытии: Aug 12, 2026, 4:00 PM EDT

3.40

-0.06 (-1.73%)

После закрытия: Aug 12, 2026, 4:57 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

NeOnc Technologies Holdings, Inc. (NTHI)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

NeOnc Technologies Holdings, Inc. (NTHI)

Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer

NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence

NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout

NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Видео

No Data

Пресс-релизы

Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer

NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence

Search stocks

NeOnc Technologies Holdings, Inc. (NTHI)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

NeOnc Technologies Holdings, Inc. (NTHI)

Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer

NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence

NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout

NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Видео

No Data

Пресс-релизы

Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer

NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence